IP Library › Granted Patent US 12,274,780
Granted Patent B2
US 12,274,780 · App. 17/517,533 · Granted Apr 15, 2025

Method of treating osteoarthritis

Inventors: Yoshinari Kumagai (Foster City, CA); Dawn McGuire (Orinda, CA); Meghan Miller (Antioch, CA); David Rosen (New Braunfels, TX)
Assignee: OrthoTrophix, Inc.
A61K9/0019A61B5/055A61B5/103A61B5/4504A61B5/4514A61B5/4528A61B5/4585A61K38/16A61K38/1709A61P19/02C07K14/47A61B5/4824
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 12,274,780
App. No.
17/517,533
Filed
Nov 2, 2021
Granted
Apr 15, 2025
Kind
B2
Art Unit
1674
USPC
514/16.8
Abstract

A method of treating osteoarthritis by modifying the shape change of bone(s) underlying articular cartilage, comprising evaluating the bone shape of the patient's joint, injecting the patient with a peptide of SEQ ID No. 1 or applying other therapeutic interventions that can reduce the shape change of the bone(s) underlying articular cartilage, and thereafter evaluating the bone shape of the patient's joint is disclosed.

Claims (9)

1. A method of delaying or reducing pathological bone shape change of a subchondral bone in a joint of a patient having osteoarthritis, comprising:

(i) obtaining a first image of the subchondral bone using magnetic resonance imaging (MRI), and measuring three-dimensional (3D) bone shape of the subchondral bone from the first MRI image, thereby diagnosing pathological bone shape change of the subchondral bone and osteoarthritis progression in the joint;

(ii) administering by local injection into the joint a therapeutically effective amount of a formulation comprising a pharmaceutically active peptide set forth in SEQ ID NO: 1, and a pharmaceutically acceptable, injectable carrier;

(iii) obtaining a second image of the subchondral bone using MRI, and measuring 3D bone shape of the subchondral bone from the second MRI image;

(iv) comparing the 3D bone shape measured from the first MRI image and the second MRI image, and determining responsiveness of the 3D bone shape change to the peptide injection; and

(v) repeating the injection until the pathological bone shape change in the joint is delayed or reduced, wherein the measuring and comparing of 3D bone shape are performed using active appearance modelling (AAM).

2. The method of claim 1 , wherein the repeating of injection is over a period of weeks, and the pharmaceutically active peptide is administered in an amount in a range of 50 to 400 mg±20%.

3. The method of claim 1 , wherein the joint is a knee joint.

4. The method of claim 1 , wherein the subchondral bone is a femur.

Assignments (1)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Apr 8, 2022
From: KUMAGAI, YOSHINARI; MCGUIRE, DAWN; MILLER, MEGHAN; ROSEN, DAVID
To: ORTHOTROPHIX, INC.
Reel/Frame 059542/0869 →
Continuity (6)
Continuation 16586516 · Sep 27, 2019
Provisional Application 62838712 · Apr 25, 2019
Provisional Application 62811366 · Feb 27, 2019
Provisional Application 62787881 · Jan 3, 2019
Provisional Application 62775056 · Dec 4, 2018
Related Publication 20220047501A1 · Feb 17, 2022
References Cited (61)
US 7638486B2 · Lazarov et al. · 2009 [cited by applicant]
US 7888462B2 · Middleton-Hardie · 2011 [cited by applicant]
US 8426558B2 · Middleton-Hardie · 2013 [cited by examiner]
US 8426588B2 · Makino · 2013 [cited by applicant]
US 11278413B1 · Lang · 2022 [cited by applicant]
US 20020147392A1 · Steines et al. · 2002 [cited by applicant]
US 20080096798A1 · Lazarov et al. · 2008 [cited by applicant]
US 20090062201A1 · Kumagai et al. · 2009 [cited by applicant]
US 20110105401A1 · Middleton-Hardie et al. · 2011 [cited by applicant]
US 20110202032A1 · Shih et al. · 2011 [cited by applicant]
US 20110266265A1 · Lang · 2011 [cited by applicant]
US 20160296692A1 · Agris · 2016 [cited by applicant]
US 20190388503A1 · Kumagai et al. · 2019 [cited by applicant]
US 20200002393A1 · Kumagai et al. · 2020 [cited by applicant]
US 20200009220A1 · Kumagai · 2020 [cited by applicant]
US 20200170939A1 · Kumagai et al. · 2020 [cited by applicant]
US 20220133484A1 · Lang · 2022 [cited by applicant]
CN 1559634A · 2005 [cited by applicant]
CN 103505628A · 2014 [cited by applicant]
CN 107998488A · 2018 [cited by applicant]
CN 108773893A · 2018 [cited by applicant]
KR 20180015810A · 2018 [cited by applicant]
WO WO2008091632 · 2008 [cited by applicant]
WO WO2010018407A1 · 2010 [cited by examiner]
Sayre et al., PLOS ONE, May 4, 2017, 12(5):e0176833. [cited by examiner]
Hayashi et al., Annals of Physical and Rehabilitation Medicine, 2016, vol. 59:161-169. [cited by examiner]
“Cartilage Protection and Formation Have Failed to Move DMOAD Development Forward” OrthoTrophix, 1 page (2021). [cited by applicant]
“Guidance for Industry, Clinical Development Programs for Drugs, Devices, and Biological Products Intended for the Treatment of Osteoarthritis (OA)” U.S. Department of Health and Human Services, Food and Drug Administra… [cited by applicant]
Hochberg, et al., “Efficacy and Safety of Intra-Articular Sprifermin in Symptomatic Radiographic Knee Osteoarthritis: Results of the 2-Year Primary Analysis from a 5-Year Randomised, Placebo-Controlled, Phase II Study” … [cited by applicant]
Hochberg, et al., “Efficacy and Safety of Intra-articular Sprifermin in Symptomatic Radiographic Knee Osteoarthritis: Pre-specified Analysis of 3-Year Data from a 5-Year Randomized, Placebo-Cotnrolled, Phase II Study” O… [cited by applicant]
“Osteoarthritis: Structural Endpoints for the Developments of Drugs, Devices, and Biological Products for Treatment, Guidance for Industry” U.S. Department of Health and Human Services, Food and Drug Administration, Cen… [cited by applicant]
“Patella Cartilage Thickness Change from Baseline” and “Tibiofemoral Cartilage Thickness Change from Baseline” OrthoTrophix (2021). [cited by applicant]
McGuire et al. “Significant, Sustained Improvement in Knee Function after Intra-Articular TPX-100: A Double-Blind, Randomized, Multi-Center, Placebo-Controlled Phase 2 Trail.” 2017 ACR Poster. [cited by applicant]
McGuire et al. “TPX-100 Leads to Marked, Sustained improvements in Subjects with Knee Osteoarthritis: Pre-Clinical Rationale and Results of a Controlled Clinical Trial” 2018 OARSI Poster. [cited by applicant]
McGuire et al. “Improved Knee Physical Function Correlates Significant with TF Cartilage Thickness Increase after IA TPX-100: Results of a Post Hoc Analysis” 2019 EULAR Abstract. [cited by applicant]
McGuire et al. “Improved Knee Physical Function Correlates Significantly with TF Cartilage Thickness after IA TPX-100: Results of a Post Hoc Analysis” 2019 EULAR Poster. [cited by applicant]
McGuire et al. “Study TPX-100-5: Intra-articular TPX-100 Significantly Delays Pathological Bone Shape Change at 6 and 12 Months in Moderate and Sever Tibiofemoral OA” 2019 ACR Bone Shape Poster. [cited by applicant]
McGuire et al. “Stabilization of Patellar Bone-Shape Correlates Significantly with Reduced Knee Pain Frequency After IA TPX-100 in Subjects with Bilateral Patellofemoral OA” 2019 ACR Pain Abstract. [cited by applicant]
McGuire et al. “Stabilization of Patellar Bone-Shape Correlates Significantly with Reduced Knee Pain Frequency after IA TPX-100 in Subjects with Bilateral Patellofemoral OA” 2019 ACR Pain Poster. [cited by applicant]
McGuire et al. “Study TPX-100-5: Intra-Articular TPX-100 Significantly Delays Pathological Bone Shape Change and Stabilizes Cartilage in Moderate to Sever Bilateral Knee OA” 2021 ART Paper. [cited by applicant]
Karsdal et al., “Disease-modifying treatments for osteoarthritis (DMOADs) of the knee and hip: lessons learned from failures and opportunities for the future” Osteoarthritis and Cartilage (2016) 24(12)2013-2021. [cited by applicant]
McGuire et al., “TPX-100 Leads to the Marked, Sustained Improvements in Subjects with Kneww Osteoarthritis: Pre-Clinical Rationale and Results of a Controlled Clinical Trial” Osteoarthritis and Cartilage (2018) 26(1):52… [cited by applicant]
Walsh et al., “Treating People With Joint Pain” International Association for the Study of Pain (2016) pp. 1-4. [cited by applicant]
Hu et al., “Joint level-set shape modeling and appearance modeling for brain structure segmentation” NeuroImage, 36:672-683 (2007). [cited by applicant]
McGuire, “TPX-100 Leads to Marked, Sustained improvements in Subjects with Knee Osteoarthritis: Pre-Clinical Rationale and Results of a Controlled Clinical Trial” Abstracts for Osteoarthritis and Cartilage, 26:#463 (201… [cited by applicant]
Neogi et al., “MRI-based three dimensional bone shape of the knee predicts onset of knee osteoarthritis: Data from the Osteoarthritis Initiative” Arthritis Rheum, 65(8):2048-2058 (2013). [cited by applicant]
Orthotrophix, “A Randomized, Double-blind, Placebo-controlled, Multi-dose Phase 2 Study Evaluating the Safety and Efficacy of Intra-articular Injections of TPX-100 in Subjects with Mild to Moderate Patello-Femoral Osteo… [cited by applicant]
Perry et al., “Measurement of synovial tissue volume in knee osteoarthritis using a semiautomated MRI-based quantitative approach” Magn Reason Med, 81:3056-3064 (2019). [cited by applicant]
AC-100 from https://www.drubank.ca.drugs/DB05671, pp. 1-3. Accessed Apr. 4, 2020 (Year 2020). [cited by applicant]
Bork, “Powers and Pitfalls in Sequence Analysis: The 70% Hurdle.” Genome Research 10:398-400 (2000). [cited by applicant]
Bowie et al., “Deciphering the Message in Protein Sequences: Tolerance to Amino Acid Substitutions” Science, 247:1306-1310 (1990). [cited by applicant]
Burgess et al., “Possible Dissociation of the Heparin-binding and Mitogenic Activities of Heparin-binding (Acidic Fibroblast) Growth Factor-1 from Its Receptor-binding Activities by Site-Directed Mutagenesis of a Single… [cited by applicant]
Christensen et al., “FAM20C-Mediated Phosphorylation of MEPE and Its Acidic Serine- and Aspartate-Rich Motif” JBMRPlus (WOA) 4(8):1-8 (Aug. 2020). [cited by applicant]
Knee Injury and Osteoarthritis Outcome Score from https://www.physio-pedia.com/KneePInjury_Osteoarthritis_Outcome_Score, pp. 1-8. Accessed Mar. 29, 2020 (Year 2020). [cited by applicant]
Lazar et al., “Transforming Growth Factor ox: Mutation of Aspartic Acid 47 and Leucine 48 Results in Different Biological Activities” Mol. Cell Biol., 8:1247-1252 (1988). [cited by applicant]
Li et al., “Subchondral bone in osteoarthritis: insight into risk factors and microstructural changes” Arthritis Research & Therapy, 15:233, pp. 1-12 (2013). [cited by applicant]
Maheswaran et al. “A Study to Investigate the Osteogenic Potential of Peptide AC-100,” EC Orthopaedics, Jan. 31, 2017 (Jan. 31, 2017), vol. 5, Iss. 3, pp. 82-87. [cited by applicant]
Roemer et al. “An illustrative overview of semi-quantitative MRI scoring of knee osteoarthritis: lessons learned from longitudinal observational studies” Osteoarthritis and Cartilage 24:274e289 275 (2016) (Year: 2016). [cited by applicant]
Rowe et al. “MEPE has the properties of an osteoblastic phosphatonin and minhibin,” Bone, Nov. 26, 2003 (Nov. 26, 2003), vol. 34, Iss. 2, pp. 303-319. [cited by applicant]
Vincent, G. et al. “Fully Automatic Segmentation of the Knee Joint using Active Appearance Models. Medical Image Analysis for the Clinic: A Grand Challenge.” Webpage [online]. Dec. 2009. Retrieved from the internet: <UR… [cited by applicant]
WOMAC Osteoarthritis Index from https://www.physio-pedia.com/WOMAC_Osteoarthritis_Index, pp. 1-6. Accessed Mar. 29, 2020 (Year: 2020). [cited by applicant]